🇺🇸

Distress Insolvency

· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — May 14, 2026

The USA Bankruptcy & Insolvency stream features a single high-materiality (10/10) Chapter 11 filing by Society Pass Incorporated (SOPA), signaling acute financial distress in the travel and media sectors. No period-over-period financial trends are detailed in the filing, but the voluntary petition implies severe liquidity constraints and operational challenges culminating in bankruptcy on May 12, 2026. Key developments include joint administration in the Southern District of Texas, operations continuing as debtors-in-possession, and a default under the Prepetition Insurance Agreement with automatic stay on enforcement. Equity trading on Nasdaq is deemed highly speculative with substantial risks, likely leading to significant shareholder value erosion. Negative sentiment dominates, with no bullish indicators from insider activity, capital allocation, or forward-looking guidance beyond first-day motions. Portfolio-level implications highlight insolvency risks for small-cap travel/media firms amid economic pressures.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 13, 2026

Across 34 filings in the USA Corporate Distress & Bankruptcy stream, a mixed landscape emerges with 4 prominent Nasdaq compliance failures signaling acute distress (delisting risks for CEA Industries, Intrusion, Reviva, Ryvyl), offset by robust revenue growth in biotechs and energy firms (e.g., Aquestive +66% YoY, Eos +445% YoY, Allogene R&D expenses -36% YoY). Period-over-period trends show revenue expansion in 7/34 companies (avg +100% YoY where reported) but persistent losses narrowing in 4 cases, alongside heavy dilution from equity offerings/ATM (Nuvve 55% shares, iSpecimen, CEL-SCI) and debt refinancings (Tempus $350M notes, LVS $1B notes). Capital allocation leans toward financings (12 new facilities/offerings) and buybacks ($206M total in Prestige/ACV), with M&A/acquisitions in 5 firms indicating strategic pivots amid distress. Portfolio-level patterns highlight small-cap Nasdaq vulnerabilities (3/34 bid price/annual meeting issues) and biotech resilience (positive trials/guidance in Allogene/Aquestive/Armata), but overall sentiment skews mixed/neutral with 10/34 filings showing dilution risks. Critical implications include near-term catalysts like Nuvve stockholder vote (Jul 27) and Reviva delisting (May 14), urging monitors for liquidity crunches in distressed names.

34 high priority 34 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 12, 2026

Across 36 filings in the USA Corporate Distress & Bankruptcy stream, key themes include Nasdaq listing non-compliance and imminent delistings in small caps (4/36 filings: Maison Solutions, Beauty Health, BIO-Key, with suspensions starting May 13, 2026), heavy reliance on dilutive equity/debt conversions and warrant issuances (6/36: Functional Brands, Securetech, Firefly, Perfect Moment, XCF Global), and ongoing debt forbearances signaling liquidity strains (Vivakor with $11.9M outstanding). Counterbalancing positives dominate larger caps with debt refinancings at lower rates (e.g., Sezzle -290bps spread, Procaccianti to 6.50%, Cinemark -0.25%, DHI extension to 2029), asset sales for non-dilutive cash (MacroGenics $122.5M), and M&A/debt-to-equity swaps (Diversified $1.175B acquisition, NSTS $73.7M buyout). Period-over-period trends limited but notable: OptimizeRx Q1 rev -10% YoY to $19.8M but adj EBITDA +120% to $3.3M, cash -14% QoQ to $20.2M; American Woodmark plant closure for $7.5M annual savings but $36-40M charges. No outright bankruptcies, but 11/36 exhibit clear distress signals vs 15 positive financings, indicating micro-cap vulnerability amid proactive deleveraging in mid/large caps. Forward catalysts cluster in Q2-Q3 2026 (compliance plans by late June, deal closes Q3), with portfolio-level margin trends unavailable but dilution risks elevated in 20% of filings.

36 high priority 36 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 11, 2026

Across 42 filings in the USA Corporate Distress & Bankruptcy stream, overarching themes include a surge in capital raisings (debt/equity offerings in 15+ companies) to bolster liquidity amid mixed Q1 2026 results, with revenue growth in select firms (e.g., Cronos +40% YoY) offset by declines (Buzzfeed -12.4% YoY, ZoomInfo NRR 90%) and margin compressions (Cronos -1pp gross margin, FS KKR higher non-accruals 4.2%). Distress signals proliferate with 4 delisting notices/threats (Purple, Picard, Allied Gaming), 2 major cybersecurity incidents (CB Financial, West Pharmaceutical), and guidance cuts (ZoomInfo FY rev lowered to $1.185-1.205B from $1.247-1.267B), but countered by M&A positives (Emerald 42% premium buyout) and capital returns (FS KKR $300M buyback, Cronos $50M repurchase renewal). Period-over-period trends show NAV declines (FS KKR -10% QoQ to $18.83), EBITDA improvements in cannabis (Cronos +122% YoY), but operational disruptions from cyber/closures (Autoliv $142M charge). Portfolio-level patterns reveal small-cap vulnerability (delistings, equity raises at discounts), BDC resilience via value actions, and financing optimism (e.g., Ares, Booking €1.9B notes). Market implications: Opportunities in turnaround financings but heightened risks from cyber, listings, and weakening metrics signal broader distress monitoring.

42 high priority 42 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 08, 2026

Across 47 filings in the USA Corporate Distress & Bankruptcy stream, a prominent theme is Nasdaq compliance distress with 5 companies (Nukkleus, Aditxt, Humacyte, Rockwell Medical, Cryo-Cell) receiving delisting notices or extensions due to sub-$1 bid prices over 30 consecutive days, signaling valuation weakness and liquidity strains without explicit YoY/QoQ declines but amid dilutive raises. Counterbalancing this, 20+ filings highlight capital raises via equity offerings, warrant exchanges, and ATM programs (e.g., Cellectar $35M, New Horizon $20M, Galaxy Digital $500M ATM), providing liquidity but risking further dilution; no period-over-period revenue/margin data disclosed, but operational metrics like Cellectar's 83.6% ORR show pockets of strength. M&A and deal activity remains resilient with premium increases (Two Harbors to $12/share, 21% premium) and large contracts (Digi Power X $1.1B MSA), while credit amendments vary (PEDEVCO expanded to $250M max, Investcorp cut to $50M). Forward-looking catalysts cluster in Q3 2026 (merger closes, asset sales) and Nov 2026 (listing cures), with no insider trading reported but governance shifts (Permian Basin majority vote amendments) easing future changes. Overall, distress signals are concentrated in small-cap biotechs/miners (listing risks, low-price financings), but broader portfolio shows proactive refinancing amid no outright bankruptcies, implying turnaround potential vs deepening insolvency.

47 high priority 47 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 07, 2026

Across 50 filings in the USA Corporate Distress & Bankruptcy stream dated May 7, 2026, a dominant theme is aggressive capital raising via convertible notes, senior debt, equity offerings, and PIPEs (e.g., ProPetro $600M upsized, Avalo $405M net proceeds), signaling liquidity bolstering amid potential distress but with positive sentiment in 60% of cases. Period-over-period trends show mixed results: revenue growth in 8/15 reporting companies (avg +35% YoY, e.g., MP Materials +49%, Resolute management fees +1073%), but persistent net losses/cash burn (e.g., MP -$8M, Kodiak -$35M FCF) and margin compression (Fox Factory -150 bps EBITDA margin). M&A activity highlights value extraction with take-private premiums (Cross Country 31%, Catalyst 21%), while distress signals cluster in small caps: 4 Nasdaq non-compliance notices (Polar Power equity $144K vs $2.5M req, Smart Powerr delisting risk May 12), covenant waivers/forbearances (Mercer €370M facility, Wellgistics $1.77M loan, Buzzfeed $5M repayment default). Capital allocation leans toward buybacks/debt paydown (Life Time $63M repurchase, Ocugen $33M loan repayment) over dividends. Portfolio-level, healthcare leads positive catalysts (3 acquisitions/offerings), energy/mining mixed operational ramps but funding dependency; implications include short-term stabilization but heightened bankruptcy risk for non-compliant microcaps.

50 high priority 50 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 06, 2026

Across 43 filings in the USA Corporate Distress & Bankruptcy stream, financing activities dominate with 25+ companies announcing debt issuances, credit amendments, or equity offerings to enhance liquidity, refinance maturities, or fund growth, signaling proactive balance sheet management amid neutral-to-positive sentiments rather than outright distress. Period-over-period trends show mixed earnings: 6/10 reporting companies posted revenue growth (avg +12% YoY, e.g., Solstice +10%, Texas Pacific +21%), but margins compressed in 4/6 (avg -150 bps, e.g., Solstice -277 bps EBITDA margin), with EBITDA flat/declining in several despite sales beats. Capital allocation leans toward shareholder returns (dividends declared by Solstice, Texas Pacific, Carriage) and buybacks/repurchases (Maplebear $349M, Alkami $100M authorized), while forward guidances are mostly reaffirmed or provided positively (Solstice FY26 sales $3.9-4.1B, Maplebear Q2 GTV +11-13%). True distress signals are sparse (1 delisting notice, 1 payables advance, 1 goodwill impairment), but outliers like Sadot's Nasdaq issues and MSP Recovery's restructuring aid highlight pockets of vulnerability. Sector patterns emerge in energy/real estate (facility expansions, e.g., Permian $3B credit) and tech/pharma (financings for commercialization). Implications: Low systemic distress but watch liquidity-dependent firms; opportunities in refinancings enabling M&A/growth.

43 high priority 43 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 05, 2026

Across 48 filings in the USA Corporate Distress & Bankruptcy stream (38 new), distress signals cluster in micro-cap Nasdaq/NYSE compliance failures (7 companies citing bid price < $1 or equity < $2.5M), plant closures, and widening losses (e.g., Rayonier sales -10% YoY, net loss doubled), but are overshadowed by 20+ positive catalysts including M&A/divestitures (12 deals totaling $2B+ value), debt refinancings/extensions (8 instances extending maturities 3-5 years), equity offerings ($500M+ raised), and guidance raises (INTEST FY rev to $130-135M, DigitalOcean FY26 +26%, ONITY ROE 10-15%). Period trends show revenue growth averaging +18% YoY in reporting firms (e.g., INTEST +27%, Bowhead premiums +24%, DigitalOcean +22%), margin expansions in 6/15 cases (INTEST +400bps gross), but compressions/declines in others (BrightView Development EBITDA -44%, Rayonier op loss widened); no insider trades reported, capital allocation favors growth/reinvestment over buybacks/dividends. Portfolio-level: Small-cap distress creates short opportunities, while mid-caps pursue consolidation/deleveraging for resilience. Implications: Monitor delisting risks for downside, pivot to M&A plays for alpha amid improving liquidity.

48 high priority 48 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 04, 2026

Across 43 filings in the USA Corporate Distress & Bankruptcy stream, the dominant theme is proactive distress resolution through M&A (e.g., GNL-Modiv $535M all-stock deal, Assertio-Garda $153M tender), equity offerings (Cabaletta $150M, Rein $50M), and debt amendments/extensions (Track Group net debt -63% to 2.6x leverage, Alcoa maturity to 2028), offsetting outright distress like SG Echo Chapter 11 bankruptcy and Nasdaq delisting risks (Hoth, Jaguar). Period-over-period trends show resilient revenue growth in select names (Ameresco +14% YoY Q1 2026, Lattice +42% YoY Q1 revenue to $170.9M) but mixed profitability (Ameresco net loss widened to $18.3M YoY, Lattice op cash flow margin -10.1pp QoQ). Capital allocation leans toward deleveraging and shareholder alignment (Track Group PIPE + new board owning 75%, Turtle Beach $49M buybacks), with forward-looking catalysts clustered in Q2-Q3 2026 (multiple M&A closings, Modiv vote). Portfolio-level patterns reveal biotech/pharma heavy (10+ filings) pursuing financings amid dilution risks, industrials consolidating via acquisitions, and sparse insider sales but new director additions signaling conviction. Overall, signals point to turnaround opportunities outweighing pure bankruptcies, with 7/43 filings showing margin stability or gains (Lattice +100bps YoY gross margin). Market implication: Distressed assets trading at premiums in M&A (Modiv 17-28%, Garda 63% to unaffected), favoring event-driven strategies.

43 high priority 43 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — May 04, 2026

The single filing in the USA Bankruptcy & Insolvency stream highlights a major distress event for Olenox Industries Inc. (formerly Safe & Green Holdings Corp., SGBX), as its wholly-owned subsidiary SG Echo LLC filed voluntary Chapter 11 on April 28, 2026, in the Eastern District of Oklahoma, triggering a $4M loan default stay. No period-over-period financial trends are detailed, but the bankruptcy underscores underlying operational or liquidity pressures absent from prior disclosures. Parent company operations continue normally with the subsidiary operating as debtor-in-possession (DIP), suggesting contained impact but high materiality (10/10) and negative sentiment. Market implications include potential sharp equity downside, heightened volatility, and short-term trading opportunities in distressed assets. Portfolio-level pattern: isolated subsidiary restructuring amid broader insolvency watchlist, with no cross-filing comparisons available.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 01, 2026

Across 50 8-K filings dated around May 1, 2026, corporate distress signals are rampant in the US small/mid-cap space, with 12 companies (24%) facing Nasdaq delisting risks primarily from sub-$1 bid prices (e.g., Curis, Rekor, CBAK) or low MVLS (Atara), signaling liquidity crunches and potential trading suspensions by Oct 2026. High-cost, dilutive financings dominate (e.g., NextNRG 203% APR loan, iQSTEL 94% VWAP equity line, PDS $6M note), reflecting cash burn pressures absent explicit YoY declines but inferred from repeated bridge/ATM raises (10+ instances). Larger firms show resilience via favorable refinancings (Herbalife $45M annual interest savings post-$1.45B refi, McCormick $2B term loan for M&A) and equity raises (National Healthcare 44M+ shares). One outright Ch11 bankruptcy (Charles & Colvard asset sale June 22) and liquidation plan (Origin Materials, 59% workforce cut saving $14M/yr). No broad insider selling patterns, but equity grants (e.g., National Healthcare 995k shares to execs) indicate retention focus; capital allocation tilts to survival (debt extensions like Diameter -23% facility but +2yr maturity). Portfolio trend: margin-neutral sentiment (28 neutral, 12 positive, 10 mixed/negative), with Oct 2026 as key catalyst cliff for delistings amplifying volatility.

50 high priority 50 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 30, 2026

Across 48 filings in the USA Corporate Distress & Bankruptcy stream (41 new), the dominant theme is corporate resilience through aggressive debt refinancing, facility expansions, and capital raises, with 12+ companies amending/extending credit lines (e.g., FTAI Aviation's $2.025B oversubscribed facility up from $400M) amid few outright bankruptcies but notable Nasdaq compliance failures. Period-over-period trends show mixed revenue (e.g., Martin Marietta +17% YoY to $1.36B, ProPetro -7% QoQ to $271M) and profitability (e.g., Tiptree EPS +162% YoY to $0.34, BayFirst net loss widened to $5.7M QoQ), with EBITDA pressures in energy (ProPetro -29% QoQ) offset by strong cash flows (Martin Marietta ops cash record $227M). Capital allocation leans toward deleveraging (FTAI Infra selling for $1.52B to repay $300M debt) and shareholder returns ($251M Martin Marietta Q1). Forward-looking catalysts cluster in Q3 2026 (M&A closings like ACRES/ACC, MARA/Long Ridge), signaling potential turnarounds, though Nasdaq delistings/threats (5 cases) and covenant waivers (Trinseo) flag ongoing distress risks. Portfolio-level, real estate/finance sectors show 8/10 amendments positive for liquidity, while small caps face equity dilution from raises. Implications: Buy dips in refinancing winners, short Nasdaq laggards; alpha in accretive M&A.

48 high priority 48 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 29, 2026

Across 43 filings in the USA Corporate Distress & Bankruptcy stream, a mixed landscape emerges with 7 clear distress signals (delistings, late filings, Nasdaq deficiencies) countered by robust M&A activity (7 deals valued $130M-$1.9B) and financing amendments (12+ credit facilities/loans totaling billions), suggesting restructurings and strategic pivots amid challenges. Period-over-period trends are sparse but highlight Vulcan Materials' outlier strength (+7% YoY revenue to $1.756B, +16% gross profit, +9% adj EBITDA at 25.5% margin) vs. flat/declining peers; no widespread margin compression but settlement burdens like Atkore's $136.5M hit. Forward-looking catalysts cluster in Q3 2026 (multiple M&A closings, e.g., OppFi, KalVista, TWO Harbors), with Nasdaq appeals/hearings in May. Capital allocation leans defensive (divestitures like Aterian $18M sale, Vulcan $217M returns) over aggressive buybacks/dividends. Portfolio-level patterns show microcaps/pharma/tech dominant in distress (Sangamo delisting, INVO/Vestand late 10-Ks), while banks/fintech pursue accretive acquisitions (OppFi +25% EPS 2027, Hawthorn +20% EPS). Implications: Opportunistic M&A in distress names offers turnaround alpha, but monitor compliance risks for short volatility.

43 high priority 43 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 28, 2026

Across 50 8-K filings in the USA Corporate Distress & Bankruptcy stream (43 new), distress signals are evident in 12 companies with Nasdaq delisting notices or non-compliance (e.g., 6 explicit cases like GIFTIFY regaining compliance, others ongoing), 3 bankruptcy proceedings (Direct Digital, Commercial Vehicle Group, Ares Capital), and 3 director departures (Flexsteel, CVG, Mainz Biomed), signaling governance and liquidity strains in microcaps and industrials. Offset by 18 financings/debt raises totaling >$11B (e.g., American Airlines $1.14B EETCs, SharonAI $350M notes, McKesson $5B revolver), often dilutive or covenant-relieving, indicating proactive distress mitigation amid no broad YoY revenue declines but mixed operational trends (Sleep Number Q1 in-line, Rocket cash runway to Q2 2028). Period-over-period insights show neutral-to-positive liquidity extensions in biotechs (5/7 with extended runways), but high dilution in microcaps (e.g., 20/20 Biolabs warrants cut 75-80%). Portfolio-level patterns: 40% high/medium risk filings cluster in biotech/industrials; capital allocation favors debt over equity returns (no dividends/buybacks noted). Implications: Short-term volatility from closings/delisting resolutions, alpha in post-financing rebounds, caution on bankruptcies.

50 high priority 50 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — April 28, 2026

Office Properties Income Trust (OPI) filed for Chapter 11 bankruptcy on April 28, 2026, marking a high-risk insolvency event in the office REIT sector amid persistent remote work trends and high interest rates. Key period-over-period trends reveal severe deterioration: Q1 2026 revenue plunged 22% YoY to $118M from $152M, with occupancy dropping to 65% from 82% YoY, and AFFO turning negative at -$0.15/share vs $0.45/share YoY. The filing highlights unsustainable $2.1B debt load (D/E ratio 5.8x, up 45% YoY), suspended dividends, and a restructuring plan targeting emergence in 12-18 months. Market implications include potential 70-90% equity wipeout, distressed asset sales, and sector contagion risks for other office landlords. No insider buying detected, signaling low management conviction, while forward guidance flags $500M debt reduction via asset sales.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 27, 2026

Across 31 filings in the USA Corporate Distress & Bankruptcy stream, themes reveal a bifurcated landscape: robust M&A activity (e.g., Organon acquired for $11.75B EV, XOMA for $739M) and capital raises (e.g., Auddia $10.9M net, Velo3D $50M) signal strategic rescues amid distress, while restatements, late filings, and reverse splits (Driven Brands, Gulf Resources, Jaguar Health) underscore ongoing reporting and compliance woes. Period-over-period trends show mixed financial health, with Fulcrum Therapeutics' Q1 2026 net loss widening 7% YoY to $18.9M (R&D +5% YoY, G&A +16% YoY) contrasting positive guidance raises (Ligand 2026 revenue to $270-310M from $245-285M). Credit facility amendments dominate (10+ filings, e.g., SiteOne, Morgan Stanley Direct Lending $1.45B commitments), suggesting proactive liquidity management but potential covenant strains. No widespread bankruptcy filings, but 4/31 exhibit acute distress signals like delisting risks and financial restatements. Forward-looking catalysts cluster in H2 2026 (e.g., Fulcrum registration trial, multiple deal closes), with capital allocation favoring equity offerings (7 cases) over dividends/buybacks. Portfolio-level: positive sentiment in 11/31 (35%), negative in 4/31 (13%), implying selective turnaround opportunities amid neutral refinancing noise.

31 high priority 31 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 24, 2026

Across 48 filings in the USA Corporate Distress & Bankruptcy stream, a dominant theme is Nasdaq delisting risks from sub-$1 bid prices affecting 7 companies (Triller Group, SHF Holdings, Standard BioTools, Nuvve Holding, NexGel, Medicus Pharma, Zeo Energy), with compliance deadlines clustered around October 19-20, 2026, signaling widespread microcap distress. Counterbalancing this, 12 companies pursued liquidity enhancements via credit facility expansions or amendments (e.g., PDF Solutions +$30M to $70M revolver, Trane Technologies $1.5B new facility, AEVEX $375M total commitments), indicating proactive refinancing amid potential stress. Positive capital raises via equity offerings (e.g., Altimmune $211M net, Elmet IPO $109M net) and M&A (e.g., Peoples Bancorp acquiring Citizens National, Helix acquiring Hornbeck) suggest turnaround efforts, though mixed with litigation and defaults (Splash Beverage, urban-gro). No broad period-over-period revenue/margin trends available, but equity deficits (Mannatech -$5.2M vs $2.5M required) and contract terminations (Spire Global Can$71.8M potential lost) highlight deteriorating financials in outliers. Overall, portfolio-level pattern shows distress concentrated in Nasdaq-listed small caps, with credit actions providing near-term buffers but dilution risks from offerings; investors should prioritize monitoring delisting appeals and Q2 2026 catalysts for short opportunities.

48 high priority 48 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 23, 2026

Across 40 filings in the USA Corporate Distress & Bankruptcy stream (April 23, 2026), a dual narrative emerges: aggressive capital raising via equity offerings ($325M Nektar, $18M Lucid), debt amendments/extensions (Paycom $2.125B revolver, Green Plains extension to 2027), and M&A (TruBridge $26.25/share acquisition, GCI Liberty $310M Quintillion buy) signals resilience in select names, but pervasive distress in small caps with 10+ Nasdaq compliance failures (late 10-Ks in Clean Energy/Borealis/Lottery.com, low equity in Boxlight, bid price/delisting in Triller/zSpace/Mawson). Limited period-over-period data shows MaxLinear revenue +43% YoY/+1% QoQ to $137.2M but GAAP op loss worsening to -13% margin QoQ; no broad portfolio declines but dilution risks from offerings/reverse splits (Immunic 1:10). Forward catalysts cluster imminently (offerings closing Apr 23-24, MaxLinear call Apr 23), with extensions like VolitionRx to Aug 2027 mitigating short-term delistings. Portfolio-level: 60% neutral/positive sentiment on financing, 25% negative on listings; themes of covenant relief (Digital Turbine liquidity to $15M) and terminated deals (Semnur $120M SPAs) underscore liquidity strains. Implications: Short-term trading opps in catalysts, but systemic small-cap distress risks forced financings/delistings, favoring larger refinancings over microcaps.

40 high priority 40 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 22, 2026

Across 37 filings in the USA Corporate Distress & Bankruptcy stream, a dominant theme is widespread listing compliance distress, with 10+ companies (e.g., Vivos, Greenwave, Graf, Apimeds, BIO KEY, Tevogen, La Rosa, EON) receiving Nasdaq/NYSE notices for late 10-Ks, negative equity (-$1.55M at Vivos), or market value shortfalls ($50M MVLS/$15M MVPHS at Tevogen), signaling acute financial reporting and balance sheet pressures amid no bankruptcies but high delisting risks. Positive counter-trends include robust financings (e.g., HIVE $100M notes, TuHURA $50M credit, Firefly $8M units, Hepion $700K equity) and M&A/divestitures (Amneal $1.1B biosimilars deal, NHC $560M facilities, Certara $135M sale, Spire $75M divestiture) to extend runways and refocus operations. Period-over-period data shows mixed revenue growth: ServiceNow +22% YoY subscription revenues ($3,671M Q1), Amneal +4% YoY ($723M Q1) with +750bps gross margins to 44.3%, contrasting distress signals; guidance raised at Amneal (Adj EBITDA $740-770M FY26) and ServiceNow (subscription $15.735-15.775B FY26). Capital allocation leans toward debt/equity raises over returns, with ServiceNow repurchasing 20.1M shares. Portfolio-level patterns highlight small-cap biotech/healthcare (Spruce, TuHURA, Hepion) and tech (Greenwave, Tevogen) as distress hotspots, while larger caps like ServiceNow outperform; implications include short-term volatility from compliance deadlines (June-Oct 2026) and alpha in turnaround financings/M&A.

37 high priority 37 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 21, 2026

Across 45 filings in the USA Corporate Distress & Bankruptcy stream (33 new), small-cap distress dominates with 12 companies (e.g., Expensify, Atlantic American, Fly-E Group, Allied Gaming, Society Pass, ENDRA Life Sciences, Aimei Health) receiving Nasdaq deficiency notices for late 10-Ks, low bid prices (<$1), low equity (<$2.5M), or missed shareholder meetings, signaling widespread compliance risks and potential delistings by Q3/Q4 2026. Positive offsets include accretive M&A (SoundHound AI acquiring LivePerson at 22% premium for $500M rev opportunity; Brady acquiring Honeywell PSS at 8x EBITDA, double-digit EPS accretive; NHI divestiture deleveraging to 2.3x net debt/EBITDA) and financings ($90M Prelude Therapeutics offering, $15M Surf Air), but debt restructurings (Reborn Coffee forbearance, NKGen $40M consolidated note) highlight liquidity strains. Limited period data shows mixed trends: Driven Brands Q4 SSS flat (0.3-0.5%) vs FY +3.5-3.7%, Take 5 SSS Q4 +1% vs FY +6.2%; NHI loses $39.7M 2025 lease rev from divestiture. No insider selling clusters, but sparse activity (e.g., Howard Hughes director investing $10M warrants); forward guidance flags H2 2026 catalysts like deal closes (SOUN/LPSN, Onto/Rigaku 27% stake). Portfolio implication: Small-cap consolidation via M&A amid delisting pressures, favor deleveraging plays over compliance laggards.

45 high priority 45 total filings